Jacobs Levy Equity Management, Inc Cyma Bay Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $725,609 - $1.12 Million	-171,539 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $292,625 - $461,153	-51,069 Reduced 22.94%	171,539 $985,000
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $260,981 - $569,129	-78,609 Reduced 26.1%	222,608 $1.61 Million
Q2 2020 Aug 17, 2020	BUY	$1.41 - $4.25 $364,649 - $1.1 Million	258,617 Added 607.08%	301,217 $1.05 Million
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $217,511 - $351,498	-174,009 Reduced 80.33%	42,600 $63,000
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $221,789 - $988,880	166,759 Added 334.52%	216,609 $425,000
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $255,232 - $359,418	49,850 New	49,850 $255,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.